MSA allows collaboration on full suite of ViroCell’s viral vector manufacturing companies to speed up the most cancers heart’s medical growth of novel gene-modified cell therapies
Settlement follows ViroCell’s profitable GMP manufacture and launch of a lentivirus vector for the most cancers heart’s medical analysis of a novel engineered TCR remedy
LONDON & NEW YORK, July 23, 2024–(BUSINESS WIRE)–ViroCell Biologics (“ViroCell” or the “Firm”) a cell and gene remedy (“CGT”) contract growth and manufacturing group (“CDMO”) specializing in GMP viral vector manufacturing for medical trials, publicizes the signing of a five-year Grasp Providers Settlement (“MSA”) with a outstanding U.S. NCI-designated most cancers heart.
Beneath the MSA, the most cancers heart may have entry to ViroCell’s full vary of pre-clinical and medical viral vector companies to speed up its medical growth of novel gene-modified cell therapies. Pre-clinical companies accessible embody viral vector design, MicroBatch© and pre-clinical batch manufacturing and course of growth. Medical companies embody international plasmid sourcing, GMP manufacturing, expedited high quality management launch testing, regulatory submitting help, and in-house Certified Individual (QP) batch assessment and approval for export and use in international medical trials.
The signing of the MSA follows the profitable GMP manufacture of a lentivirus vector by ViroCell to be used by the most cancers heart within the medical analysis of a novel engineered T cell receptor (TCR) remedy, for the therapy of quite a lot of cancers. The vector was launched to the most cancers heart for medical use lower than 5 months after the beginning of GMP manufacture.
John W. Hadden II, CEO at ViroCell, commented:
“We’re delighted to have signed this Grasp Providers Settlement with one of many world’s premier most cancers analysis facilities. It additional underscores our capability to supply extremely specialised GMP viral vector manufacturing companies to cutting-edge analysis teams each in academia and trade as they translate their science into next-generation cell and gene therapies. We sit up for working carefully with the scientists at this prestigious establishment, as they begin thrilling new most cancers drug growth packages.”
Notes to editor:
ViroCell
ViroCell Biologics is an innovation-driven Contract Growth and Manufacturing Group (“CDMO”) targeted solely on the design, derisking, and GMP manufacture of viral vectors for medical trials. Constructed round probably the most prolific tutorial viral vector manufacturing groups, ViroCell was created to handle the worldwide demand for exactly engineered viral vectors and goals to turn out to be the companion of selection for corporations growing cell and gene therapies. The crew leverages its deep monitor report to assist shoppers to de-risk and speed up novel cell and gene therapies into and thru medical growth, with a mission of being the companion of selection for company and tutorial innovators on this discipline. Targeted initially on manufacturing lentivirus and gamma-retrovirus vectors, ViroCell allows shoppers to start out medical trials on a scalable platform, delivering worth by decreasing prices, time and regulatory threat.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240722521261/en/
Contacts
For extra ViroCell data, please contact:
ViroCell
John W. Hadden II, CEO
information@virocell.com
For ViroCell media enquiries, please contact:
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Tim Stamper
ViroCell@fticonsulting.com
+44 (0)20 3727 1000
